Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gerpferon
- Development stage
- Unknown
- Lead developer
- Firn-M
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Gerpferon (Герпферон) is an approved topical combination drug developed by the Russian pharmaceutical company Firn M for the treatment of herpetic infections. The formulation contains three active components: recombinant interferon alfa-2b, the antiviral agent acyclovir, and the local anesthetic lidocaine. Recombinant interferon alfa-2b acts by binding to the interferon alpha/beta receptor (IFNAR) on cell surfaces, triggering an antiviral and immunomodulatory response that helps the body combat the herpes virus. Acyclovir is a guanosine analogue that selectively inhibits viral DNA polymerase, thereby preventing the replication of herpes simplex virus (HSV) and varicella-zoster virus (VZV). Lidocaine provides symptomatic relief by blocking voltage-gated sodium channels, which reduces the pain and itching associated with herpetic lesions. Gerpferon is approved in Russia for the management of herpetic infections of the skin and mucous membranes, including herpes simplex types 1 and 2, genital herpes, and herpes zoster.
- Brand names
- Gerpferon
- Other names
- Герпферонinterferon alfa-2b + acyclovir + lidocaine
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)DNA polymerase family
Beyond the preview
Go deeper on Gerpferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gerpferon.